Trastuzumab With Carboplatin, Paclitaxel Improves PFS in Uterine Serous Carcinoma

Share this content:
Toxicity was similar in both arms.
Toxicity was similar in both arms.
The following article features coverage from the Society of Gynecologic Oncology 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Adding trastuzumab to carboplatin and paclitaxel is safe and effective among patients with advanced or recurrent uterine serous carcinoma with overexpressed HER2/neu, according to a presentation at the 2018 Society of Gynecologic Oncology Annual Meeting on Women's Cancer in New Orleans.1

Carboplatin/paclitaxel is an established treatment for uterine serous carcinoma, a rare and aggressive subtype of endometrial cancer. For this phase 2 study (ClinicalTrials.gov Identifier: NCT01367002), researchers evaluated whether adding trastuzumab, which inhibits HER2/neu, to this combination would improve outcomes among patients with advanced/recurrent disease with overexpressed HER2/neu. The primary endpoint was progression-free survival (PFS).

Sixty-one patients were randomly assigned to receive carboplatin/paclitaxel or carboplatin/paclitaxel with trastuzumab. All patients had stage III to IV primary or recurrent disease. Fifty-eight patients were evaluable for PFS.

The overall median PFS was 12.6 in the trastuzumab arm vs 8 months in the control arm (hazard ratio [HR], 0.44; P = .005). Patients treated for primary disease (41 patients) had a median PFS of 17.9 months in the trastuzumab arm vs 9.3 in the control arm (HR, 0.40; P = .013); patients with recurrent disease (17 patients) had a median PFS of 9.2 vs 6 months in the experimental vs control arm, respectively (HR, 0.14; P = .003).

Toxicity was similar in both arms.

The authors concluded that adding “trastuzumab to carboplatin-paclitaxel was well-tolerated and increased PFS. This regimen may come to represent the new standard of care for women with advanced or recurrent uterine serous carcinoma who overexpress Her2/neu.”

Read more of Cancer Therapy Advisor's coverage of the Society of Gynecologic Oncology 2018 meeting by visiting the conference page.

Reference

  1. Santin AD, Fader AN. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002). Oral presentation at: 2018 Society of Gynecologic Oncology Annual Meeting on Women's Cancer; March 24-27, 2018; New Orleans, LA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs